Science 37® Extends Market-Leading Capabilities in Decentralized Clinical Trial Execution
New additions to the Science 37 executive team will enhance both the patient and sponsor experiences as well as extend patient recruitment and trial execution efficiencies
Jan 14, 2020, 08:55 ET
LOS ANGELES, Jan. 14, 2020 /PRNewswire/ -- Science 37, the industry leader in decentralized clinical trials, recently announced that Jonathan Commons and Darcy Forman have joined the company as vice president of patient engagement and vice president of clinical operations, respectively. The additions help Science 37 extend its market-leading capabilities in clinical trial services and delivery of enhanced experiences for both patients and sponsors.
"Adding Jonathan and Darcy to our executive team enables us to extend our leadership in the decentralized trials market," said David Coman, CEO of Science 37. "Jonathan's deep experience in patient engagement coupled with Darcy's breadth of experience in clinical operations, set us on an exhilarating path that will allow us to create additional value for sponsors and further enhance the patient experience."
As vice president of patient engagement, Commons joins Science 37 from Optum, a global health services company that is part of UnitedHealth Group, where he was managing director of the Innovation Solutions Group and responsible for developing data-driven customer insights for health engagement. Prior to Optum, Commons honed his expertise at AbleTo Inc., a leading provider of virtual behavioral healthcare, where he was vice president of consumer engagement. He has also held a variety of digital strategy and marketing leadership positions at GlaxoSmithKline and IQVIA. As vice president of patient engagement at Science 37, Commons will oversee all aspects of patient recruitment and engagement, including the entire patient journey.
"Joining Science 37 is a rare opportunity to be at the forefront of patient-centered research, and I look forward to building on the momentum Science 37 has created in transforming the patient experience and optimizing patient recruitment," Commons said.
Forman, vice president of clinical operations, joins Science 37 from Firma Clinical Research, a contract research organization (CRO), where she was most recently vice president of corporate development and had previously led global clinical operations. Prior to Firma, Forman held leadership positions in clinical operations at Clinipace Worldwide, a CRO specializing in supporting growth-oriented and mid-tier pharmaceutical and medical device companies. As vice president of clinical operations at Science 37, Forman will manage all aspects of the clinical trial life cycle, from pre-contract study planning to complete study execution.
"Science 37 has a clear mission, purpose-built technology, and a disruptive approach to clinical research. I am thrilled to have the opportunity to further enhance the sponsor experience and extend efficiencies in our clinical trial execution," Forman said.
Science 37 has conducted more fully decentralized, interventional clinical trials than any other organization. The Science 37 model has achieved enrollment timelines that are up to 27 times faster than traditional sites with 90% higher retention rates on the same trial. Research at Science 37 is powered by the industry's first and only comprehensive, purpose-built platform to fully operationalize a virtual or decentralized trial.
About Science 37
Science 37 accelerates the availability of life-changing medicines by putting patients first. Transforming the patient experience, Science 37 extends clinical trial research beyond traditional offices and hospitals and into the comfort and convenience of home. This expansive reach removes barriers to participation so that everyone can benefit from breakthrough research—anytime, anywhere. Recognized as the industry leader, our unrivaled expertise, unparalleled recruitment and retention capabilities, high-touch patient services, and comprehensive platform inspire confidence that Science 37 is uniquely qualified to execute decentralized clinical research with the highest quality, robustness, and regard for patient safety and data integrity. Learn more at Science 37, and follow Science 37 on Twitter, LinkedIn, and Facebook.
SOURCE Science 37
Share this article